Search
There are 204 result(s) found based on your search criteria
11-20 from 204 result(s)
Medication errors: 112 errors reported to the FAMHP since 2016
The FAMHP Medication errors working group has received 112 notifications of proven or potential errors since 2016. Thanks to these notifications, corrective or preventive measures were put in place, in collaboration with the pharmaceutical industry. The Agency encourages healthcare professionals and patients to report any actual or potential medication error.
Influenza vaccine: priority for at-risk groups extended
Priority for category A has been extended, but vaccines already distributed to category B can be administered.
Coronavirus: the Inter-Ministerial Conference on Public Health agrees on the European procurement procedure for Moderna vaccine candidate and finalizes COVID-19 vaccination strategy
The Inter-Ministerial Conference (IMC) on Public Health held another meeting today to discuss the different aspects of approach of the COVID-19 pandemic.
Coronavirus: EMA receives first two applications for conditional marketing authorisation of COVID-19 vaccines
The European Medicines Agency (EMA) received applications for a conditional marketing authorisation (MA) for Pfizer/BioNTech's candidate vaccine and Moderna's candidate vaccine. The evaluation of the candidate vaccines will be performed under accelerated assessment. An evaluation on the marketing authorisation could be issued within weeks, depending on whether the submitted data are sufficiently robust and complete to prove the quality, safety and effectiveness of the vaccines.
Bavencio
Active substance avelumab Holder Merck nv/sa Status Closed Indication first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) without disease progression following first-line platinum-based induction chemotherapy Public documents Approbation Information for the patient Informed consent Last update 11/08/2022
Lynparza
Active substance olaparib Holder AstraZeneca Status closed Indication patients with metastatic castration resistant prostate cancer who have progressed on prior NHA and have a BRCA mutation (germline or somatic) Public documents Approbation Information for the patient Informed consent Last update 11/08/2022
Killapods is considered to be a medicinal product
Based on the risk to the consumer, the Joint Commission’s Chamber for products for human considers Killapods nicotine pouches medicinal product by function.
Coronavirus: further extension of the measures taken by the FAMHP to avoid medicinal product shortages
On 1 April 2020, the FAMHP took steps regarding a range of medicinal products in order to avoid any shortage. These measures have now been extended by one month.
Flash VIG-news: Trisenox (arsenic trioxide): risk of medication errors due to the introduction of a new concentration of 2 mg/ml
The FAMHP warns healthcare professionals prescribing, delivering and administering Trisenox about the risk of dosing errors as a new presentation of the medicine is launched on the market.
Brexit: the FAMHP reminds marketing authorisation holders of the end of the transition period for submitting variations
Marketing authorisation holders (MAHs) are reminded that it is their responsibility to make the necessary changes to their dossiers and to submit the necessary variations before 31 December 2020.